[Congressional Record Volume 167, Number 42 (Friday, March 5, 2021)]
[Senate]
[Pages S1360-S1361]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1298. Mr. BURR submitted an amendment intended to be proposed to 
amendment SA 891 proposed by Mr. Schumer (for himself, Mr. Wyden, Mrs. 
Murray, Mr. Brown, Mr. Peters, Mr. Cardin, Ms. Cantwell, Ms. Stabenow, 
Mr. Tester, Mr. Menendez, Mr. Schatz, Mr. Carper, Mr. Leahy, and Mr. 
Sanders) to the bill H.R. 1319, to provide for reconciliation pursuant 
to title II of S. Con. Res. 5; which was ordered to lie on the table; 
as follows:
        On page 83 of the amendment, strike line 18 and all that 
     follows through line 12 on page 86, and insert the following: 
     ``$10,000,000,000, to remain available through September 30,

[[Page S1361]]

     2031, necessary expenses with respect to the research, 
     development, manufacturing, production, and purchase, at the 
     discretion of the Secretary, of vaccines, therapeutics, 
     ancillary supplies necessary for the administration of such 
     vaccines and therapeutics, and medical devices to prevent, 
     prepare for, and respond to SARS-CoV-2 or any viral variant 
     mutating therefrom with pandemic potential and COVID-19 or 
     other public health threats, of which--
       ``(1) $4,000,000,000 shall be for the Biomedical Advanced 
     Research and Development Authority to support the research, 
     advanced research, development, manufacturing, and 
     procurement of medical countermeasures, which may include 
     supporting, maintaining, and improving domestic manufacturing 
     surge capacity of medical products or platform technologies 
     for use during a public health emergency, pursuant to section 
     319L of the Public Health Service Act;
       ``(2) $1,500,000,000 shall be for the Strategic National 
     Stockpile pursuant to section 319F-2 of the Public Health 
     Service Act related to the procurement and maintenance of 
     medical products and ancillary medical supplies necessary to 
     respond to public health threats, which may include through 
     the establishment and maintenance of domestic manufacturing 
     surge capacity or vendor managed supply reserves;
       ``(3) $2,000,000,000 shall be for the National Institutes 
     of Health to support the research and development of medical 
     countermeasures, including broad-spectrum antivirals for 
     SARS-CoV-2;
       ``(4) $1,000,000,000 shall be for the Biomedical Advanced 
     Research and Development Authority to support the research 
     and development of broad-spectrum antivirals for SARS-CoV-2; 
     and
       ``(5) $1,500,000,000 shall be for the Secretary for rapid 
     screening, identification, and development of compounds and 
     platform technologies that may support preparedness for and 
     response to a potential public health threat.

     ``SEC. 2304. FUNDING FOR COVID-19 VACCINE, THERAPEUTIC, AND 
                   DEVICE ACTIVITIES AT THE FOOD AND DRUG 
                   ADMINISTRATION.

       ``In addition to amounts otherwise available, there is 
     appropriated to the Secretary for fiscal year 2021, out of 
     any money in the Treasury not otherwise appropriated, 
     $500,000,000, to remain available until expended, to prevent, 
     prepare for, and respond to COVID-19, domestically or 
     internationally, including the development and review of 
     medical countermeasures to address COVID-19 and emerging 
     variants of COVID-19, and which may be used for the 
     evaluation of the continued performance, safety, and 
     effectiveness, including with respect to emerging COVID-19 
     variants, of vaccines, therapeutics, and diagnostics 
     approved, cleared, licensed, or authorized for use for the 
     treatment, prevention, or diagnosis of COVID-19; facilitation 
     of advanced continuous manufacturing activities related to 
     production of vaccines and related materials; facilitation 
     and conduct of inspections related to the manufacturing of 
     vaccines, therapeutics, and devices delayed or cancelled for 
     reasons related to COVID-19, including modernizing inspection 
     processes; facilitation of the use of real world evidence and 
     real world data for approved, cleared, licensed, or 
     authorized medical products; review of devices authorized for 
     use for the treatment, prevention, or diagnosis of COVID-19; 
     and oversight of the supply chain and mitigation of shortages 
     of vaccines, therapeutics, and devices approved, cleared, 
     licensed, or authorized for use for the treatment, 
     prevention, or diagnosis of COVID-19 by the Food and Drug 
     Administration.

     ``SEC. 2305. REDUCED COST-SHARING.

       ``(a) In General.--Section 1402 of the Patient Protection 
     and Affordable Care Act is amended by redesignating 
     subsection (f) as subsection (g) and by inserting after 
     subsection (e) the following new subsection:
       `` `(f) Special Rule for Individuals Who Receive 
     Unemployment Compensation During 2021.--For purposes of this 
     section, in the case of an individual who has received, or 
     has been approved to receive, unemployment compensation for 
     any week beginning during 2021, for the plan year in which 
     such week begins--
       `` `(1) such individual shall be treated as meeting the 
     requirements of subsection (b)(2), and
       `` `(2) for purposes of subsections (c) and (d), there 
     shall not be taken into account any household income of the 
     individual in excess of 133 percent of the poverty line for a 
     family of the size involved.'.
       ``(b) Effective Date.--The amendment made by this section 
     shall apply to plan years beginning after December 31, 2020.

                         ``Subtitle E--Testing

     ``SEC. 2401. FUNDING FOR COVID-19 TESTING, CONTACT TRACING, 
                   AND MITIGATION ACTIVITIES.

       ``(a) In General.--In addition to amounts otherwise 
     available, there is appropriated to the Secretary of Health 
     and Human Services (in this subtitle referred to as the 
     `Secretary') for fiscal year 2021, out of any money in the 
     Treasury not otherwise appropriated, $40,080,000,000, to 
     remain available until expended, to''.
                                 ______